Buscar literatura

Resumen con IA

• Pharmacovigilance analysis evaluating reported sexual dysfunction associated with SSRIs and SNRIs.
• The study uses adverse-event reporting data to compare reporting patterns and signal strength across antidepressant exposures.
• Findings support an association between serotonergic antidepressant exposure and reported sexual dysfunction, including concern for persistent symptoms after discontinuation.
• As a reporting-database study, results are hypothesis-generating and limited by reporting bias, confounding, and inability to estimate true incidence.

Generado con IA a partir del texto completo (HTML). Consulte siempre el artículo original.

Resumen con IA

• Narrative review discussing SSRI safety concerns, proposed mechanistic pathways, and unresolved clinical questions.
• It synthesizes evidence on adverse effects, including sexual dysfunction and potential persistence after treatment.
• The paper emphasizes uncertainty in biological mechanisms and highlights major knowledge gaps in long-term outcomes and risk stratification.
• The review supports stronger informed-consent practice and calls for better prospective research to clarify causality and recovery trajectories.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This consensus review from the fifth International Consultation on Sexual Medicine examines sexual dysfunction in psychiatric disorders and during psychotropic medication treatment.
• The committee used literature searches and a modified Delphi-style consensus process to develop clinical recommendations.
• The review reports that sexual dysfunction is common across psychiatric disorders and is also a frequent treatment-emergent adverse effect, with antidepressant-associated sexual dysfunction estimated at 25% to 80% and antipsychotic-associated sexual dysfunction at 16% to 60%, depending on medication mechanism.
• The authors recommend routine sexual-function assessment, recognition that sexual dysfunction is often multifactorial, and longitudinal monitoring when prescribing psychotropic medications.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This qualitative study explored the experiences of people with post-SSRI sexual dysfunction (PSSD).
• Ten participants were recruited through a patient advocacy group and interviewed using semi-structured interviews; the results were analyzed using descriptive phenomenological analysis.
• Findings indicate that people with PSSD can experience psychological, physical, and sexual effects of withdrawal that cause suffering, hopelessness, and alienation, and that healthcare providers often lack understanding, awareness, and acceptance of PSSD.
• The lack of healthcare provider knowledge and support compounded the suffering of those with PSSD and contributed to a lack of trust in physicians and reliance on self-care to manage symptoms.

Generado con IA a partir del resumen (abstract) y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a case study investigating the peripheral nature of persistent sexual dysfunction associated with post-finasteride, post-SSRI, and post-accutane syndromes.
• Three male patients were treated with high frequency electrical stimulation and low intensity extracorporeal shock wave therapy for 16 weeks, and their symptoms were assessed using various measures.
• The study found mild-moderate improvements in erectile function, penile sensitivity, and nocturnal erections, as well as evidence of peripheral neuropathy in two patients, but central symptoms remained profoundly affected.
• The authors conclude that the post-drug syndrome has a peripheral component that may be treatable, but additional research is urgently needed to fully understand and address this condition.

Generado con IA a partir de un extracto en HTML y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Conference review abstract summarizing 15 years of literature on PSSD symptom patterns and candidate biological mechanisms.
• It outlines persistent sexual symptom domains and discusses hypothesized pathways involving serotonergic, neurosteroid, and neurobiological signaling changes.
• The abstract highlights ongoing uncertainty in pathophysiology and lack of validated biomarkers or definitive treatment pathways.
• Because this is supplement abstract content, methodological detail is limited and conclusions should be interpreted as preliminary synthesis.

Generado con IA a partir del resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Conference abstract describing neurological assessment of genital numbness in individuals reporting enduring sexual dysfunction after SSRI exposure.
• The work focuses on objective neurologic evaluation of sensory symptoms that are often described in PSSD.
• Findings support the clinical value of formal neurological workup in patients with persistent post-SSRI genital sensory complaints.
• As abstract-level evidence, sample size and detailed methods are limited, so findings should be considered preliminary.

Generado con IA a partir del resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Mechanistic conference abstract exploring paroxetine-related dopamine dysregulation as a potential contributor to PSSD pathogenesis.
• The authors present translational/preclinical rationale linking serotonergic drug exposure to downstream dopaminergic changes relevant to sexual function.
• The work supports a model where persistent neurotransmitter-network alterations may underlie enduring sexual symptoms after SSRI discontinuation.
• Evidence is preliminary at abstract level and requires full-study validation for stronger clinical interpretation.

Generado con IA a partir del resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a review article examining the relationship between the gut microbiome, gut steroids, and the brain.
• Only bibliographic metadata was available for this source, as the full-text article is paywalled and could not be accessed.
• The main findings and claims of this review are not known due to the limited information provided.
• Further details about the evidence basis, methods, and practical relevance of this work cannot be determined from the available metadata.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This animal study examined the transcriptomic profile in the hypothalamus and nucleus accumbens of male rats after paroxetine treatment and withdrawal, to investigate potential mechanisms underlying paroxetine-induced sexual dysfunction.
• The study used RNA sequencing to analyze gene expression changes in the two brain regions at the end of 2 weeks of paroxetine treatment (T0) and 1 month after withdrawal (T1). Limitations include the animal model and lack of a control group.
• The results showed significant changes in genes related to neurotransmitters, inflammation, and signaling pathways involved in sexual behavior and reward processing, particularly in the nucleus accumbens at both timepoints.
• The persistent dysregulation of these genes after withdrawal suggests they may contribute to post-SSRI sexual dysfunction, though further research is needed to confirm the mechanisms and clinical relevance.

Generado con IA a partir de un extracto en HTML y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This cross-sectional survey study aimed to estimate the frequency of persistent post-treatment genital hypoesthesia (PPTGH), a symptom of post-SSRI sexual dysfunction (PSSD), among past users of psychiatric treatments, particularly antidepressants, in a sample of sexual and gender minority youth in Canada and the US.
• The study used a subsample of the UnACoRN survey of 15-29 year olds, including participants with a history of psychiatric drug use and excluding those with genital surgeries or no sexual experience. The analysis involved statistical tests to compare groups and estimate the odds of PPTGH by drug type.
• The frequency of PPTGH was 13.2% among antidepressant users, compared to 0.9% among users of other medications. The adjusted odds ratio was 14.2, indicating a strong association between antidepressant discontinuation and PPTGH.
• The findings underscore the urgent need for transparent patient education and informed consent regarding the persistent sexual dysfunction risks associated with antidepressants, particularly for young patients. Further research is needed to fully characterize the prevalence and risk factors of PSSD.

Generado con IA a partir de un extracto en HTML y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Editorial commentary examining post-SSRI sexual dysfunction (PSSD), an iatrogenic condition where sexual side effects persist after discontinuing serotonin reuptake inhibitor antidepressants.
• Full-text peer-reviewed editorial synthesizing academic literature, clinical experience, and regulatory history; no original empirical data or sample sizes presented.
• Multiple obstacles prevent accurate PSSD prevalence quantification: ethical constraints on study design, patient embarrassment, healthcare provider dismissiveness, antidepressant withdrawal preventing discontinuation, and lack of public awareness.
• Existing prevalence estimates vary widely (0.46% to 52.6%) due to methodological differences and selection bias; no established treatments exist; regulatory adoption of diagnostic criteria remains incomplete.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This review examines the sexual dysfunction induced by antidepressant medications.
• The evidence basis is limited to bibliographic metadata, as the full text could not be accessed.
• The review likely summarizes current research on the sexual side effects of antidepressant drugs.
• Further details on the review's scope, methods, and conclusions are unavailable without the full text.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This review article discusses two SSRI-related sexual dysfunction syndromes: post-SSRI sexual dysfunction and persistent genital arousal disorder.
• The evidence base for these syndromes remains limited, with no consensus on epidemiology, diagnostic criteria, or treatment guidelines.
• Post-SSRI sexual dysfunction can involve genital anesthesia, pleasureless/weak orgasms, diminished sexual drive, erectile dysfunction, or premature ejaculation, while persistent genital arousal disorder is characterized by spontaneous and unrelenting subjective sexual arousal.
• Clinicians should be vigilant in considering these syndromes when evaluating psychotropic-related sexual dysfunction in psychiatric patients.

Generado con IA a partir del texto completo (HTML). Consulte siempre el artículo original.

Resumen con IA

• This book provides evidence-based guidelines for safely deprescribing antidepressants, benzodiazepines, gabapentinoids, and Z-drugs.
• The evidence basis is limited to bibliographic metadata, as the full text was not available for review.
• The guidelines aim to help clinicians and patients navigate the process of discontinuing these medications.
• Further details on the specific recommendations and supporting evidence are needed to fully assess the utility and validity of the guidelines.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Case-study report examining psychological and sexual functioning in people affected by PSSD.
• The paper describes persistent sexual symptoms alongside meaningful psychological burden and impact on daily life.
• Findings highlight the need for multidisciplinary clinical assessment that includes both sexual medicine and mental-health perspectives.
• Because the design is case-based, generalizability is limited and larger controlled studies are needed.

Generado con IA a partir del texto completo (HTML). Consulte siempre el artículo original.

Resumen con IA

• This review examines the clinical conditions of post-finasteride syndrome and post-SSRI sexual dysfunction, which appear distinct but may have underlying similarities.
• Only bibliographic metadata was available to summarize, as the full-text article is paywalled and could not be accessed.
• The main findings and claims of the review are not known due to the limited source material.
• Further research with full access to the article would be needed to provide a more comprehensive summary of the study's content and conclusions.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a review article that discusses rare male sexual disorders, including post-finasteride syndrome, restless genital syndrome, post-orgasmic illness syndrome, post-selective serotonin reuptake inhibitor (SSRI) sexual dysfunction, hard-flaccid syndrome, sleep-related painful erections, and post-retinoid sexual dysfunction.
• The evidence for these disorders comes primarily from case-control trials or small case series, and the published literature is limited. The exact mechanisms underlying these conditions are not fully understood, and the optimal investigational work-up and therapy are not well defined.
• The authors highlight the need for larger-scale studies, including prospective trials and comprehensive case registries, to better understand the aetiology, prevalence, and clinical characteristics of these rare sexual disorders. Collaborative efforts among researchers, healthcare professionals, and patient advocacy groups are also crucial to develop evidence-based guidelines and novel therapeutic approaches.
• By advancing the understanding and refining treatment strategies for these rare sexual disorders, the authors aim to improve the quality of life and foster healthier sexual relationships for individuals suffering from these conditions.

Generado con IA a partir de un extracto en HTML y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a systematic review examining the relationship between selective serotonin reuptake inhibitors (SSRIs), post-treatment sexual dysfunction, and persistent genital arousal disorder.
• The evidence basis is limited to bibliographic metadata, as the full-text article is paywalled and not accessible.
• The main findings or claims could not be summarized due to the lack of access to the full study details.
• The practical relevance of this review is unclear without access to the full text.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a review article examining the sexual side effects of antidepressants, post-SSRI sexual dysfunction, and serotonin syndrome.
• The evidence basis is limited to bibliographic metadata, as the full text of the article is paywalled and not accessible.
• The main claims and findings of the article are not available due to the limited source material.
• The practical relevance and limitations of the review cannot be determined from the available information.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This observational study aimed to estimate the risk of erectile dysfunction (ED) and post-SSRI sexual dysfunction (PSSD) in males treated with serotonergic antidepressants (SAs).
• The study used a 19-year retrospective cohort analysis of a database from the largest HMO in Israel, including 12,302 males aged 21-49 with no medical or psychiatric comorbidities, medications associated with ED, or substance use.
• SAs were associated with a significantly increased risk for ED, with a crude odds ratio of 3.6 and an adjusted odds ratio of 3.2 after controlling for factors like age, BMI, and depression/anxiety. The risk for PSSD was estimated at 1 in 216 patients (0.46%) treated with SAs.
• This study provides the first assessment of the small but significant risk of irreversible ED associated with commonly prescribed serotonergic antidepressants, which should inform the informed consent process for patients starting this treatment.

Generado con IA a partir del texto completo (HTML). Consulte siempre el artículo original.

Resumen con IA

• This is a literature review on post-SSRI sexual dysfunction (PSSD) and SSRI-induced sexual dysfunction.
• The review examines available PubMed data on the epidemiology, symptoms, and treatment of SSRI-related sexual dysfunction, including both dysfunction that occurs during SSRI use and that which persists after discontinuation.
• SSRI-induced sexual disorders are more common but easier to treat, while post-SSRI sexual dysfunction is less common and harder to treat, with several hypothesized pathomechanisms like epigenetic changes and serotonin receptor downregulation.
• There are no effective treatments for post-SSRI sexual dysfunction, and the diagnosis is difficult due to lack of specific criteria, requiring more research to determine how to diagnose and treat this condition.

Generado con IA a partir de un extracto en HTML y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a case study examining the pathophysiology of Post SSRI Sexual Dysfunction (PSSD).
• The evidence basis is limited to a single case study, and full details of the methods and sample are not available.
• The main findings or claims are not accessible without the full text of the article.
• Caution is warranted in generalizing from a single case, and practical relevance is unclear without the complete study details.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a reference work providing comprehensive information on prescribing, dispensing, and administering medicines in the UK.
• The source material is limited to bibliographic metadata, as the full text was not available.
• The BNF84 edition contains up-to-date guidance on drug use, interactions, and safety for healthcare professionals.
• As a paywalled resource, access may be limited for some users, reducing the practical relevance for a nonprofit website.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This chapter discusses post-SSRI sexual dysfunction (PSSD), a disorder where impairments in sexual functioning and satisfaction continue long after stopping antidepressant medication.
• The evidence is based on a literature review, with limitations including the lack of data on prevalence, pathophysiology, and effective treatments for PSSD.
• Key symptoms of PSSD include genital anesthesia, erectile dysfunction, and pleasureless orgasm, which are unrelated to any pre-existing mental health or medical condition.
• Medical recognition of PSSD is critical to investigate its true prevalence, underlying mechanisms, and potential treatments to help those affected by this persistent sexual dysfunction.

Generado con IA a partir de un extracto en HTML y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This observational study aimed to investigate the effects of a novel treatment for post-SSRI sexual dysfunction in males.
• The study was limited to bibliographic metadata, as the full text was not available for review.
• The main findings or claims could not be determined from the provided metadata.
• Without access to the full study details, the confidence in summarizing this literature is low.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a review article examining the screening and treatment of sexual dysfunctions associated with selective serotonin reuptake inhibitor (SSRI) medications.
• Only bibliographic metadata was available for this summary, as the full-text article is behind a paywall and could not be accessed.
• The review likely examines the prevalence, risk factors, assessment, and management of SSRI-induced sexual side effects based on the available literature.
• Without access to the full text, the specific details, quality, and conclusions of this review cannot be determined.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This observational study examines a multimodal approach to treating post-selective serotonin reuptake inhibitor sexual dysfunctions (PSSD).
• The study is based on clinical experience, but the specific sample size and methods are not provided in the available metadata.
• The main findings or claims about the multimodal treatment approach are not available in the provided source material.
• Without access to the full study details, the confidence in summarizing the practical relevance or limitations of the findings is low.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This commentary explores how the website rxisk.org seeks to convert the web from a site for misinformation into a source of new knowledge about drug side effects, by soliciting patient reports to uncover harms missed by clinical trials and pharmacovigilance schemes.
• The article traces the origins of rxisk.org to a nearly 15-year struggle to obtain recognition and redress for the ability of selective serotonin reuptake inhibitor (SSRI) antidepressants to trigger violent or suicidal behavior, which modern evidence-making practices obscured.
• The project aims to reframe the relation between anecdote and evidence to liberate the patient's voice from the burden of representativeness, and is freed from the imperative of large-scale data extraction that dominates digital health.
• The commentary reflects on the implications of modern evidence-making instruments and institutions, the relations between narration and truth, and the consequences of shifting media ecologies on the conditions of self-knowledge and self-experience.

Generado con IA a partir de un extracto en HTML y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This animal study examined the effects of the antidepressant paroxetine on steroidogenesis and gut microbiota in adult male rats.
• The study was based on bibliographic metadata only, as the full text was not available.
• The main findings or claims could not be determined from the limited information provided.
• Without access to the full study details, the confidence in summarizing this literature is low.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a mechanistic study that aimed to identify a novel off-target of the SSRI antidepressant paroxetine, which may contribute to its sexual dysfunction side effects.
• Only bibliographic metadata was available to summarize, as the full-text article is paywalled and the GET request failed with HTTP 403.
• The study claims to have identified a novel off-target of paroxetine that could play a role in the sexual dysfunction induced by this SSRI drug.
• The practical relevance and specific findings of this study are unclear due to the limited source material available.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This book provides guidance on when and how to discontinue psychopharmaceuticals, including the necessity, evidence, and process of long-term psychopharmaceutical therapy and withdrawal.
• The book is based on current scientific knowledge and is intended for medical professionals such as psychiatrists, psychotherapists, and general practitioners.
• Key topics covered include reasons for discontinuation, biological and psychological adaptation to long-term use, withdrawal symptoms, and practical steps for discontinuation.
• The book aims to equip prescribers with the knowledge to make informed decisions about whether, when, and how to discontinue psychopharmaceuticals.

Generado con IA a partir del resumen (abstract) y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This book explores the links between mental and sexual health, sexual diversity and mental health, as well as critical issues in psychiatry and sexual medicine.
• The book is a comprehensive guide for clinical practitioners, drawing on expertise from an international team of editors and contributors.
• Key topics covered include sexual dysfunctions, substance-related disorders, psychotic disorders, mood disorders, anxiety disorders, and eating disorders, among others.
• The book aims to help understand and effectively address mental health issues in sexual medicine and sexual issues in psychiatric patients.

Generado con IA a partir de un extracto en HTML y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a Freedom of Information request response from the UK Medicines & Healthcare products Regulatory Agency (MHRA) on adverse sexual dysfunction reactions associated with SSRI use.
• The MHRA received a total of 1,654 UK spontaneous suspected adverse drug reaction reports of sexual dysfunction associated with SSRIs, with varying degrees of information on whether the reaction continued after drug withdrawal.
• Of these 1,654 cases, 360 indicated that the sexual dysfunction persisted after discontinuation of the SSRI, and the MHRA followed up on 186 cases where the outcome was unknown and 95 cases where the recovery time was unknown.
• The MHRA notes that the number of reports received should not be used to determine the incidence of the reaction, as the total number of reactions and patients using the drug are not included in the data.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This scoping review examines persistent sexual dysfunction after withdrawal from selective serotonin reuptake inhibitor (SSRI) antidepressants, including a case series of 86 reports from the Netherlands.
• The review analyzed 237 articles and 86 spontaneous reports of persistent sexual dysfunction, with the longest case lasting 23 years. The main symptoms were decreased libido, erectile dysfunction, and anorgasmia.
• The review found that post-SSRI sexual dysfunction (PSSD) can have significant sexual, psychological, and social consequences, but the underlying mechanisms are poorly understood and no effective treatments exist.
• The authors call for increased recognition of PSSD among prescribers and improved clinical management, as little is known about this condition and its long-term impacts.

Generado con IA a partir del resumen (abstract) y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Expert consensus article developing diagnostic criteria for four enduring sexual dysfunction syndromes: post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD), post-finasteride syndrome (PFS), and post-retinoid sexual dysfunction (PRSD).
• Methods based on two published case series (Hogan et al. 2014, Healy et al. 2018) representing largest public data collections, refined by multidisciplinary expert panel. No randomized controlled trials or prevalence studies conducted.
• PSSD, PFS, and PRSD share features including decreased genital sensation, reduced sexual desire, and erectile dysfunction persisting three months or longer after drug discontinuation. PGAD presents opposite pattern with unwanted genital arousal absent sexual desire.
• Criteria lack biomarkers and represent consensus framework intended for clinical and research settings. Authors acknowledge criteria will require modification as evidence develops and may eventually be replaced by genetic or electrophysiological diagnostic markers.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This study was a survey of individuals with post-SSRI sexual dysfunction (PSSD) to characterize the condition and its impact on quality of life.
• The survey was distributed to an online PSSD support group and assessed medications, symptoms, treatment efficacy, and quality of life impacts. 239 responses were included.
• The majority of respondents had a history of SSRI use (92%), and 45% reported symptom improvement after discontinuation, while 37% worsened or remained the same. Most rated the impact on quality of life as extremely or very negative.
• Further research is needed to understand why some develop PSSD and to identify effective treatments, as this condition can have a severe negative impact on quality of life.

Generado con IA a partir del resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This study was a survey that aimed to provide a comprehensive picture of the demographic and clinical characteristics associated with post-SSRI sexual dysfunction (PSSD).
• The survey was conducted online with 135 subjects (115 males, mean age 31.9 years) who self-reported as being affected by PSSD after exposure to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).
• The results showed that PSSD was more common among young, heterosexual males who had taken relatively high doses of SSRIs/SNRIs, and that symptoms could persist both during and after medication use, suggesting an iatrogenic effect.
• Further research is needed to better understand this complex iatrogenic syndrome of PSSD.

Generado con IA a partir del resumen (abstract) y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This animal study examined the effects of paroxetine treatment and withdrawal on neurosteroidogenesis in male rats.
• The study evaluated neuroactive steroid levels and expression of steroidogenic enzymes in the brain and bodily fluids of rats treated with paroxetine for two weeks and/or after a month of withdrawal.
• The results indicate that paroxetine treatment altered neuroactive steroid levels and steroidogenic enzyme expression in a brain region- and time-dependent manner, suggesting a direct effect on neurosteroidogenesis.
• The findings suggest that altered neurosteroidogenesis may contribute to post-SSRI sexual dysfunction, and could represent a potential pharmacological target for this condition.

Generado con IA a partir del resumen (abstract) y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Cross-sectional study comparing sexual dysfunction domains in 117 former SSRI/SNRI users versus 123 controls with no antidepressant history using online questionnaires.
• Sample of 240 adults (67.9% female, mean age 29.84 years) from 40 countries completed the Changes in Sexual Functioning Questionnaire and three additional items measuring genital anesthesia, nipple insensitivity, and orgasms without pleasure.
• Former SSRI users reported significantly higher antidepressant-associated sexual dysfunction symptoms and lower sexual pleasure than controls; no significant differences in frequency, desire, arousal, or orgasm domains.
• Study provides tentative support for post-SSRI sexual dysfunction as distinct condition but notes measurement limitations and calls for stricter controls, baseline assessments, and gender-specific research in future studies.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This observational study aimed to retrospectively review the medical records of patients with post-SSRI sexual dysfunction (PSSD) over a 10-year period.
• The study was limited to the available metadata, as the full text was paywalled and not accessible.
• The main findings or claims could not be determined from the provided metadata.
• Without access to the full study details, the confidence in summarizing this literature item is low.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a review article examining the sexual side effects of antidepressant medications.
• The evidence basis is limited to bibliographic metadata, as the full-text article is paywalled and not accessible.
• The main findings or claims of the article are not available due to the limited source material.
• The practical relevance of this review is unclear without access to the full text.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This commentary discusses post-SSRI sexual dysfunction, a condition characterized by persistent sexual side effects after discontinuing selective serotonin reuptake inhibitor (SSRI) antidepressant medications.
• The available evidence is limited to case reports and observational studies, as the full text of this article was not accessible.
• The commentary suggests that post-SSRI sexual dysfunction may be underreported and underrecognized, and calls for more research to understand the condition.
• Practical relevance includes the need for clinicians to be aware of this potential adverse effect when prescribing SSRIs and to monitor patients carefully.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a historical review article examining the relationship between antidepressants and sexual dysfunction.
• Only bibliographic metadata was available for this paywalled article, so the evidence basis, methods, and sample details are unknown.
• The article likely discusses the history of how antidepressants have been associated with sexual side effects over time.
• Without access to the full text, the specific claims and practical relevance of this review cannot be determined.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This observational study examined the relationship between antidepressant use during development and women's sexual desire in adulthood.
• The study is limited to bibliographic metadata, as the full text was not available.
• The main findings or claims could not be determined from the provided information.
• Further details are needed to assess the quality and practical relevance of this research.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a case report examining sexual dysfunction or withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs).
• The evidence is limited to a single case study, and full details of the methods and findings are not available without access to the paywalled article.
• The case report discusses a patient's experience with sexual dysfunction and withdrawal symptoms following SSRI discontinuation, but the specific claims and conclusions are unclear from the metadata alone.
• Further research with larger samples and more detailed reporting would be needed to fully understand the potential risks and mechanisms involved in SSRI-related sexual dysfunction and withdrawal.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Regulatory guidance document from the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) adopted May 2019, recommending updates to product information for four medications based on safety signals.
• Full text document containing PRAC recommendations for product labeling changes. Source material includes summary of product characteristics and package leaflet sections for clopidogrel, pantoprazole, SNRIs/SSRIs, and sertraline.
• PRAC identified four safety signals: clopidogrel interaction with boosted HIV therapy reducing platelet inhibition; pantoprazole association with microscopic colitis; SSRIs/SNRIs causing persistent sexual dysfunction after discontinuation; sertraline association with maculopathy.
• Document is regulatory guidance for healthcare product labeling, not original clinical research. Recommendations based on spontaneous reports and demonstrated pharmacological interactions, with acknowledged uncertainties about clinical relevance in some cases.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This master's thesis examines the impact of persistent sexual dysfunction after discontinuing antidepressant medication on quality of life.
• The study is based on metadata only, as the full text was not available.
• The main findings or claims could not be determined from the limited information provided.
• Without access to the full thesis, the confidence in summarizing this work is low.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This study proposes a hypothesis about the potential bioelectric mechanism underlying post-SSRI sexual dysfunction.
• The evidence basis is limited to bibliographic metadata, as the full article text is paywalled and not accessible.
• The authors suggest that SSRI-induced changes in cellular bioelectricity may contribute to the development of persistent sexual side effects.
• Further research with available data would be needed to evaluate the proposed hypothesis and its practical implications.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This review article examines the potential sex/gender differences in post-selective serotonin reuptake inhibitor (SSRI) sexual dysfunction (PSSD).
• The available literature lacks a clear definition of PSSD and has limited data on sex/gender differences, though some gender differences in symptom frequency are reported.
• The review finds the scientific literature lacks profound information about the extent, mechanism, and treatment of PSSD, as well as sex/gender differences.
• The author recommends that physicians assess sexual function before, during, and after antidepressant treatment, and inform patients about potential sexual side effects to aid treatment decision-making.

Generado con IA a partir de un extracto en HTML y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a review article examining the potential for persistent adverse effects of antidepressant medications.
• The evidence basis is limited to metadata, as the full text of the article is not available.
• The review likely examines existing research on long-term side effects of antidepressants, but the specific claims and findings are unknown.
• The practical relevance of this review is unclear without access to the full text.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a review article examining post-SSRI sexual dysfunction (PSSD) and other enduring sexual dysfunctions following treatment with selective serotonin reuptake inhibitor (SSRI) antidepressants.
• The evidence is based on a review of the literature, including reports to regulators since 1991 and case studies describing PSSD, persistent genital arousal disorder (PGAD), post-finasteride syndrome (PFS), and post-retinoid sexual dysfunction (PRSD).
• The main findings indicate that SSRI treatment can cause immediate sexual effects like genital numbing and delayed ejaculation, and in some cases these effects persist long after treatment is stopped, leading to syndromes like PSSD characterized by genital anesthesia, loss of libido, and sexual dysfunction.
• The author notes the clinical, research, and regulatory implications of these enduring sexual syndromes, and suggests that epidemiological methods could help map the scope of the problem and identify potential treatments, though the underlying mechanisms remain unclear.

Generado con IA a partir de un extracto en HTML y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This qualitative study explored patient experiences of engaging with healthcare professionals regarding post-SSRI sexual dysfunction.
• The study was based on bibliographic metadata only, without access to the full text.
• The main findings or claims could not be determined from the limited information provided.
• Further details from the full text would be needed to assess the evidence basis and practical relevance of this study.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a case study examining the use of nutraceuticals to address post-SSRI sexual dysfunction.
• The study is limited to a single case report, so the evidence basis is very narrow.
• The case study reports improvements in sexual function after using a nutraceutical supplement, but the findings require further validation in larger studies.
• More robust research is needed to determine the efficacy and safety of nutraceuticals for post-SSRI sexual dysfunction.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• EMA pharmacovigilance report reviewing EudraVigilance safety data on persistent sexual dysfunction associated with antidepressants.
• The evidence is based on spontaneous post-marketing adverse-event reports and signal evaluation context, not controlled incidence studies.
• The report supports regulatory concern that sexual dysfunction can persist after antidepressant discontinuation in some patients and informs warning-label discussions.
• Key limitations include under-reporting, inconsistent report quality, and inability to estimate true population risk from spontaneous reports.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This is a citizen petition submitted to the FDA in April 2018 requesting enhanced labeling warnings for SSRIs and SNRIs regarding sexual side effects.
• The petition compiles case reports, animal studies, pharmacovigilance data, and published literature from 1991 to 2018, including neurophysiological studies, case series, and systematic reviews cited in 56 references.
• Evidence presented includes genital anesthesia documented in 1991 and 1999 studies showing increased penile sensory thresholds; multiple case reports of persistent sexual dysfunction lasting years after drug discontinuation; and a 2018 study of 221 cases from an adverse event reporting system.
• The petition acknowledges that most evidence derives from case reports and observational data rather than randomized controlled trials, and notes that pre-medication sexual baselines are rarely documented in clinical practice.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• Case series investigating clinical reports of persistent sexual dysfunction following treatment discontinuation with serotonin reuptake inhibitors, 5α-reductase inhibitors, and isotretinoin.
• Data from RxISK.org adverse event reporting website covering 300 cases from 37 countries; mean causality scores 8.5-8.9 suggesting likely drug links; Naranjo algorithm used but acknowledged as underestimating legacy effects.
• Common symptoms across drug groups included erectile dysfunction (86-94%), loss of libido (71-92%), genital anaesthesia (36-49%), and pleasureless orgasm (8-43%); some symptoms unique to antidepressants like premature ejaculation and persistent genital arousal disorder.
• Dysfunction often persisted years after stopping treatment; 17 subjects reported symptoms for 10+ years; secondary consequences included relationship breakdown and job loss; mechanisms remain unclear and require improved coding systems for research.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This review examines the persistent sexual dysfunction observed in patients treated with the 5alpha-reductase inhibitor finasteride or selective serotonin reuptake inhibitor (SSRI) antidepressants, known as post-finasteride syndrome (PFS) and post-SSRI sexual dysfunction (PSSD), respectively.
• The evidence is based on a review of the literature, including case reports and small studies, which suggest these conditions may be underestimated and their underlying mechanisms are not well understood.
• The review discusses potential common mechanisms between PFS and PSSD, focusing on the roles of the neuromodulators dopamine, serotonin, and neuroactive steroids in sexual function and the persistent sexual side effects observed after discontinuing these medications.
• The authors caution that more research is needed to fully characterize these conditions and their underlying causes, as the persistent sexual dysfunction can have a significant impact on patient quality of life.

Generado con IA a partir de un extracto en HTML y los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a review article examining the evidence for post-SSRI sexual dysfunction.
• Only bibliographic metadata was available for this source, as the full text is paywalled.
• The review discusses the potential mechanisms and clinical evidence for persistent sexual side effects after discontinuing SSRI medications.
• The limited metadata provided does not allow for a more detailed summary of the review's findings or conclusions.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a case report studying persistent sexual dysfunction after discontinuation of paroxetine.
• The evidence is limited to a single case study, with no details on methods, sample, or data sources provided.
• The main finding is a case of persistent sexual dysfunction following paroxetine withdrawal, as reported in the title and authors.
• The practical relevance and generalizability of this single case report are unclear without further details.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a literature review examining post-SSRI sexual dysfunction.
• The evidence basis is limited to bibliographic metadata, as the full article text was not available.
• The review likely summarizes existing research on the sexual side effects of selective serotonin reuptake inhibitor (SSRI) medications.
• Without access to the full text, the specific claims, methods, and conclusions of the review cannot be determined.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a review article examining the sexual consequences of post-SSRI syndrome, a condition that can occur after discontinuing selective serotonin reuptake inhibitor (SSRI) medications.
• The full text of this article is not publicly available, as it is behind a paywall.
• The review likely summarizes existing research on the sexual side effects that can persist after stopping SSRI antidepressants, but the specific evidence basis is unknown without access to the full text.
• Further details on the mechanisms, prevalence, and management of post-SSRI sexual dysfunction are not available in the provided metadata.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This systematic review examines animal studies on the potential for persistent sexual dysfunction after early exposure to selective serotonin reuptake inhibitors (SSRIs).
• The review is limited to the available metadata, as the full text could not be accessed.
• The metadata indicates the review found evidence of persistent sexual dysfunction in animal studies following early SSRI exposure, but details on the specific findings are unavailable.
• The practical relevance of these animal findings to human populations requires further investigation with the full study details.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a review article examining sexual dysfunction that persists after treatment with antidepressants.
• The evidence basis is limited to bibliographic metadata, as the full text of the article was not available.
• The main findings or claims of the article are not known due to the lack of access to the full text.
• Without the full text, the cautions, limitations, or practical relevance of the findings cannot be determined.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This observational study aimed to characterize post-SSRI sexual dysfunction and assess contributing factors and dose-response relationships.
• The study was limited to bibliographic metadata, as the full text was paywalled and not accessible.
• The main findings and claims could not be determined from the available metadata.
• Further research with full access to the study details would be needed to assess the validity and practical relevance of the findings.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a case report examining the use of low-power laser irradiation to treat penile anesthesia in a patient with Post SSRI Sexual Dysfunction (PSSD).
• The study is limited to a single case, and the full details of the methods and results are not available without access to the paywalled article.
• The authors claim that the low-power laser irradiation was effective in treating the patient's penile anesthesia, but the supporting evidence is not provided in the available metadata.
• Further research with larger samples and more detailed reporting would be needed to evaluate the generalizability and reliability of this treatment approach for PSSD.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Case series analysis of 120 reports of post-treatment enduring sexual dysfunction (PTESD) following SSRIs, finasteride, or isotretinoin, examining clinical presentation across three drug classes.
• Data sourced from RxISK.org adverse event reports from 22 countries; 94 subjects had age data (mean 30.9 years, 79 male, 15 female); treatment duration ranged 3 days to 15 years.
• Three drugs showed overlapping symptom profiles: loss of libido (75.4%), erectile dysfunction (64.9%), orgasm difficulties (54.4%), and genital anesthesia (30.7%); dysfunction often emerged after treatment cessation.
• Study cannot estimate condition frequency and acknowledges incomplete demographic data; proposed mechanisms remain speculative; no effective treatments identified despite multiple pharmacological approaches attempted.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This observational study examined whether sexual dysfunction persists after discontinuation of selective serotonin reuptake inhibitors (SSRIs).
• The authors searched the Netherlands Pharmacovigilance Centre database for reports of persistent sexual dysfunction in patients who had stopped using SSRIs for 2 months to 3 years.
• The database contained 19 reports of persistent sexual disorders such as reduced libido, erectile dysfunction, and delayed orgasm after SSRI discontinuation.
• The findings suggest that sexual dysfunction may not always resolve shortly after stopping SSRIs, contrary to previous assumptions, and may involve both pharmacological and psychological factors.

Generado con IA a partir del resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a diagnostic reference section from DSM-5 describing substance/medication-induced sexual dysfunction diagnostic criteria and clinical features.
• The material is from the official DSM-5 diagnostic manual published by the American Psychiatric Association in 2013, providing clinical guidelines rather than empirical research data.
• Substance/medication-induced sexual dysfunction requires temporal relationship between substance/medication use and sexual function disturbance, with specific diagnostic criteria including evidence from history and physical examination.
• Clinicians must differentiate this condition from non-substance-induced sexual dysfunctions and underlying mental disorders; prevalence varies by medication class, with antidepressants causing sexual side effects in approximately 25-80% of users depending on agent.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This qualitative study explored the impact of persistent sexual side effects after discontinuing selective serotonin reuptake inhibitor (SSRI) treatment.
• The study is based on a PhD thesis, but the full text was not available for review.
• The main findings or claims could not be determined from the limited metadata provided.
• Without access to the full study, the confidence in summarizing the research is low.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Pharmacovigilance signal report examining persistent sexual dysfunction in patients after discontinuing selective serotonin reuptake inhibitor medications.
• Analysis of 19 adverse event reports submitted to Netherlands Pharmacovigilance Centre Lareb through February 2012, plus published case reports and product labeling review.
• Reports documented sexual dysfunction persisting two months to two years after SSRI discontinuation across multiple drugs; dysfunction types included erectile dysfunction, decreased libido, ejaculatory disorders, and anorgasmia.
• Mechanism remains unknown; proposed hypotheses include delayed normalization of gene expression, endocrine alterations, and serotonergic effects on testosterone regulation, requiring further investigation.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This observational study examined persistent sexual dysfunction in patients attending a genitourinary medicine clinic who were taking selective serotonin reuptake inhibitors (SSRIs).
• The study is limited to bibliographic metadata, as the full text was not available.
• The main findings or claims could not be determined from the provided information.
• Without access to the full study details, the cautions, limitations, and practical relevance cannot be assessed.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This commentary discusses the issue of sexual side effects of antidepressant medications and the need for informed consent.
• The source material is limited to bibliographic metadata, as the full text was not available.
• The commentary claims there is an 'informed consent accountability gap' regarding the sexual side effects of antidepressants.
• Without the full text, the specific evidence basis, methods, and practical relevance cannot be determined from the provided information.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Letter to editor discussing case reports and emerging evidence of persistent sexual dysfunction after SSRI discontinuation in the absence of ongoing psychiatric symptoms.
• Evidence limited to three published case reports from psychology and gynecology journals, one additional clinical observation, and unsubstantiated Internet community reports; no systematic study or epidemiologic data provided.
• Three peer-reviewed case reports document sustained sexual dysfunction and genital anesthesia persisting after SSRI discontinuation; symptoms were absent before treatment and occurred without identifiable alternative causes.
• Author notes pharmaceutical industry unlikely to fund formal post-marketing studies due to limited documented cases, medico-legal concerns, and economic implications; calls for systematic epidemiologic investigation.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• Literature review examining evidence that sexual dysfunction side effects from SSRIs and SNRIs may persist after medication discontinuation, contrary to conventional clinical assumptions.
• Evidence drawn from case reports, incidental research findings, empirical studies on premature ejaculation treatment, Internet community reports, and gaps in existing research literature lacking systematic post-discontinuation follow-up.
• Post-market studies show SSRI/SNRI sexual side effects occur at 36-70% rates versus 2-16% in pre-market trials; some individuals report persistent genital anesthesia, anhedonic orgasm, and erectile dysfunction years after stopping medications.
• Author notes research inadequately assesses uncommon symptoms like genital anesthesia and pleasureless orgasm; lack of long-term follow-up studies and industry conflicts of interest limit detection of persistent effects and informed consent discussions.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This is a review article examining the potential for persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors (SSRIs).
• The evidence basis is limited to bibliographic metadata, as the full-text article is paywalled and not accessible.
• The main findings or claims of the article are not available due to the limited source material.
• The practical relevance of this review is unclear without access to the full text.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• Case report describing a 32-year-old woman with major depression treated with citalopram then nefazodone who experienced persistent genital anesthesia and sexual dysfunction.
• Single patient case study with clinical examination, laboratory testing for hormonal and thyroid function, neurological examination, and psychological consultation documented in the medical record.
• Patient developed genital numbness, decreased libido, and orgasmic dysfunction within days of citalopram initiation; symptoms persisted through 14-month nefazodone treatment and remained unchanged one year after drug discontinuation despite depression remission.
• Authors note persistent post-treatment sexual dysfunction may be underreported and warrant formal surveillance; mechanism remains unclear but may involve permanent serotonin receptor changes or genetic predisposition via specific polymorphisms.

Generado con IA a partir del texto completo (PDF). Consulte siempre el artículo original.

Resumen con IA

• This commentary discusses post-SSRI sexual dysfunction, a condition that can occur after discontinuing selective serotonin reuptake inhibitor (SSRI) antidepressants.
• The evidence basis is limited to bibliographic metadata, as the full text of the article was not available.
• The main claims and findings are not accessible due to the lack of the full article text.
• Further research with available full-text sources would be needed to provide a more comprehensive summary.

Generado con IA a partir de los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This case series examines persistent sexual side effects after discontinuation of selective serotonin reuptake inhibitor (SSRI) antidepressants.
• The study is limited to bibliographic metadata, as the full text was not available.
• The main findings or claims are not accessible without the full article.
• The practical relevance of this study is unclear without access to the details of the methods and results.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.

Resumen con IA

• This is a case report describing persistent genital anesthesia after discontinuation of the antidepressant sertraline.
• The evidence is limited to a single case study, with no details provided on the patient, methods, or data collection.
• The report claims that the patient experienced genital numbness for six years after stopping sertraline treatment.
• The generalizability and mechanisms of this rare adverse effect are unclear from the available metadata.

Generado con IA a partir de los metadatos – al ser de pago, puede basarse únicamente en el resumen (abstract) y los metadatos. Consulte siempre el artículo original.